Steven Powell

10PUBLICATIONS
110CO-AUTHORS
Molecular targetsAllergyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 22, 2026
Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors.

|Jan 15, 2026
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Daniel R Carrizosa, Michael Rothe, Pam K Mangat

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Oct 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Francis P Worden, Evan Pisick, Michael Rothe

|Dec 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Funda Meric-Bernstam, Michael Rothe, Pam K Mangat

|Nov 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.

Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam

Pageof 2

Frequent Collaborators

4 joint publications

Dominique C Hinshaw

4 joint publications

Deepti Behl

4 joint publications

Susan Halabi

4 joint publications

Abigail Gregory